- |||||||||| Trial completion: Sun Protection of Kidney Transplant Recipients (clinicaltrials.gov) - Apr 23, 2015
P=N/A, N=335, Completed, Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Apr 2016 Enrolling by invitation --> Completed
- |||||||||| Trial primary completion date: Potential Research Study Participant Registry (clinicaltrials.gov) - Apr 16, 2015
P=N/A, N=200, Recruiting, Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Jan 2015 --> Jan 2025
- |||||||||| sirolimus / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma (clinicaltrials.gov) - Mar 3, 2015 P2, N=1, Terminated, Trial primary completion date: Jan 2016 --> Jan 2017 N=43 --> 1 | Recruiting --> Terminated | Trial primary completion date: Nov 2014 --> Jun 2014; Poor accrual
- |||||||||| Trial completion, Enrollment change: Helping Children be Safe Outdoors With Sun Protection (clinicaltrials.gov) - Feb 24, 2015
P=N/A, N=840, Completed, N=43 --> 1 | Recruiting --> Terminated | Trial primary completion date: Nov 2014 --> Jun 2014; Poor accrual Enrolling by invitation --> Completed | N=2000 --> 840
- |||||||||| Enrollment status, Trial primary completion date: Sun Protection of Kidney Transplant Recipients (clinicaltrials.gov) - Feb 23, 2015
P=N/A, N=360, Enrolling by invitation, Enrolling by invitation --> Completed | N=2000 --> 840 Recruiting --> Enrolling by invitation | Trial primary completion date: Oct 2014 --> Apr 2015
- |||||||||| Trial primary completion date: Post-Approval Study of MelaFind (clinicaltrials.gov) - Feb 3, 2015
P=N/A, N=720, Recruiting, Recruiting --> Active, not recruiting Trial primary completion date: Dec 2014 --> Mar 2016
- |||||||||| Trial initiation date, Trial primary completion date: Reducing Skin Cancer Risk in Childhood Cancer Survivors (clinicaltrials.gov) - Jan 28, 2015
P=N/A, N=801, Enrolling by invitation, Trial primary completion date: Jan 2015 --> Jun 2016 Initiation date: Sep 2014 --> Mar 2015 | Trial primary completion date: Sep 2016 --> Apr 2018
- |||||||||| epacadostat (INCB024360) / Incyte
Enrollment closed, Combination therapy, Metastases: A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (clinicaltrials.gov) - Jan 9, 2015 P1/2, N=136, Active, not recruiting, Enrolling by invitation --> Recruiting Recruiting --> Active, not recruiting
- |||||||||| Hiltonol (poly-ICLC) / Oncovir
Trial completion, Trial initiation date, Trial primary completion date, IO biomarker: Safety Study of Adjuvant Vaccine to Treat Melanoma Patients (clinicaltrials.gov) - Jan 8, 2015 P2, N=35, Completed, Recruiting --> Active, not recruiting Not yet recruiting --> Completed | Initiation date: Nov 2014 --> Sep 2010 | Trial primary completion date: Oct 2015 --> Mar 2013
- |||||||||| Trial completion, Enrollment change, Trial primary completion date, Cytology: Nanocytology Test to Evaluate Skin Cancer in High Risk Patients (clinicaltrials.gov) - Nov 19, 2014
P=N/A, N=7, Completed, N=67 --> 0 | Terminated --> Withdrawn Recruiting --> Completed | N=30 --> 7 | Trial primary completion date: Jun 2014 --> Nov 2014
- |||||||||| Hiltonol (poly-ICLC) / Oncovir
Trial initiation date, Trial primary completion date, IO biomarker: Safety Study of Adjuvant Vaccine to Treat Melanoma Patients (clinicaltrials.gov) - Oct 28, 2014 P2, N=33, Not yet recruiting, Recruiting --> Completed | N=30 --> 7 | Trial primary completion date: Jun 2014 --> Nov 2014 Initiation date: Sep 2010 --> Nov 2014 | Trial primary completion date: Oct 2013 --> Oct 2015
- |||||||||| Hiltonol (poly-ICLC) / Oncovir
Enrollment change, Trial termination: Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC) (clinicaltrials.gov) - Oct 28, 2014 P2, N=8, Terminated, Initiation date: Sep 2010 --> Nov 2014 | Trial primary completion date: Oct 2013 --> Oct 2015 N=20 --> 8 | Active, not recruiting --> Terminated; PI discretion, low enrollment
- |||||||||| Biomarker, Enrollment open, IO biomarker, Metastases: Biomarker Correlates of Hypoxia in Metastatic Melanoma (clinicaltrials.gov) - Oct 22, 2014
P2, N=36, Recruiting, N=20 --> 8 | Active, not recruiting --> Terminated; PI discretion, low enrollment Not yet recruiting --> Recruiting
- |||||||||| Erivedge (vismodegib) / Roche
Trial completion, Enrollment change, Trial primary completion date, Surgery: Vismodegib for Treatment of Basal Cell Carcinoma (clinicaltrials.gov) - Sep 28, 2014 P2, N=3, Completed, Active, not recruiting --> Completed Not yet recruiting --> Completed | N=81 --> 3 | Trial primary completion date: Mar 2013 --> Jun 2013
- |||||||||| Veregen (sinecatechins) / Sinphar Pharma, Medigene
Trial initiation date, Trial primary completion date: Topical Green Tea Ointment in Treatment of Superficial Skin Cancer (clinicaltrials.gov) - Sep 16, 2014 P2/3, N=42, Not yet recruiting, Not yet recruiting --> Completed | N=81 --> 3 | Trial primary completion date: Mar 2013 --> Jun 2013 Initiation date: Mar 2014 --> Sep 2014 | Trial primary completion date: Dec 2014 --> Mar 2015
|